Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2008 1
2009 2
2010 9
2011 12
2012 18
2013 31
2014 56
2015 68
2016 67
2017 87
2018 90
2019 99
2020 115
2021 26
Text availability
Article attribute
Article type
Publication date

Search Results

598 results
Results by year
Filters applied: . Clear all
Page 1
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Sehn LH, et al. J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6. J Clin Oncol. 2020. PMID: 31693429 Free PMC article. Clinical Trial.
METHODS: Safety and efficacy of polatuzumab vedotin with bendamustine and obinutuzumab (pola-BG) was evaluated in a single-arm cohort. Polatuzumab vedotin combined with bendamustine and rituximab (pola-BR) was compared with bendamustine and rituximab (BR) in a randomly ass …
METHODS: Safety and efficacy of polatuzumab vedotin with bendamustine and obinutuzumab (pola-BG) was evaluated in a single-arm cohort …
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Fischer K, et al. N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4. N Engl J Med. 2019. PMID: 31166681
All-cause mortality was 9.3% in the venetoclax-obinutuzumab group and 7.9% in the chlorambucil-obinutuzumab group. These differences were not significant. CONCLUSIONS: Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was as …
All-cause mortality was 9.3% in the venetoclax-obinutuzumab group and 7.9% in the chlorambucil-obinutuzumab group. These diffe …
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Marcus R, et al. N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598. N Engl J Med. 2017. PMID: 28976863 Free article. Clinical Trial.
Response rates were similar in the two groups (88.5% in the obinutuzumab group and 86.9% in the rituximab group). Adverse events of grade 3 to 5 were more frequent in the obinutuzumab group than in the rituximab group (74.6% vs. 67.8%), as were serious adverse event …
Response rates were similar in the two groups (88.5% in the obinutuzumab group and 86.9% in the rituximab group). Adverse events of g …
A tale of two antibodies: obinutuzumab versus rituximab.
Freeman CL, Sehn LH. Freeman CL, et al. Br J Haematol. 2018 Jul;182(1):29-45. doi: 10.1111/bjh.15232. Epub 2018 May 9. Br J Haematol. 2018. PMID: 29741753 Review.
Pre-clinical data suggests obinutuzumab is superior to rituximab at effecting B cell depletion; however recent phase III clinical trial results have been mixed. ...The benefit conferred by obinutuzumab over rituximab may be context-specific and vary based on histolo …
Pre-clinical data suggests obinutuzumab is superior to rituximab at effecting B cell depletion; however recent phase III clinical tri …
Chronic lymphocytic leukemia treatment algorithm 2018.
Parikh SA. Parikh SA. Blood Cancer J. 2018 Oct 3;8(10):93. doi: 10.1038/s41408-018-0131-2. Blood Cancer J. 2018. PMID: 30283014 Free PMC article. Review.
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very effective oral targeted therapies (such as ibrutinib, idelalisib, and venetoclax), and next-generation anti-CD20 monoclonal antibodies (such as o
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very effectiv …
Recent landmark studies in follicular lymphoma.
Sorigue M, Sancho JM. Sorigue M, et al. Blood Rev. 2019 May;35:68-80. doi: 10.1016/j.blre.2019.03.006. Epub 2019 Mar 23. Blood Rev. 2019. PMID: 30928169 Review.
These studies include risk-assessment by gene expression profiling, the therapeutic strategy in localized FL, use of obinutuzumab or lenalidomide in the front-line setting, stem cell transplant in early treatment failure and phosphatidylinositol 3-kinase (PI3K) inhibition …
These studies include risk-assessment by gene expression profiling, the therapeutic strategy in localized FL, use of obinutuzumab or …
Treatment Update of Autoimmune Blistering Diseases.
Kridin K, Ahn C, Huang WC, Ansari A, Sami N. Kridin K, et al. Dermatol Clin. 2019 Apr;37(2):215-228. doi: 10.1016/j.det.2018.12.003. Epub 2019 Feb 14. Dermatol Clin. 2019. PMID: 30850044 Review.
The role of obinutuzumab in the management of follicular lymphoma.
O'Nions J, Townsend W. O'Nions J, et al. Future Oncol. 2019 Nov;15(31):3565-3578. doi: 10.2217/fon-2019-0193. Epub 2019 Sep 20. Future Oncol. 2019. PMID: 31538821 Review.
Therefore, there remains a need to develop novel therapeutic options and optimize existing regimens. Obinutuzumab (a first-in-class, glycoengineered, humanized type 2 anti-CD20 antibody) has been evaluated in a number of clinical trials. In this review, we will summarize t …
Therefore, there remains a need to develop novel therapeutic options and optimize existing regimens. Obinutuzumab (a first-in-class, …
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M. Hallek M. Am J Hematol. 2017 Sep;92(9):946-965. doi: 10.1002/ajh.24826. Am J Hematol. 2017. PMID: 28782884 Free article. Review.
For unfit patients, currently available evidence supports two options for a first-line therapy: chlorambucil combined with an anti-CD20 antibody (obinutuzumab or rituximab or ofatumumab) or a continuous therapy with ibrutinib. ...FUTURE CHALLENGES: The new agents (ibrutini …
For unfit patients, currently available evidence supports two options for a first-line therapy: chlorambucil combined with an anti-CD20 anti …
598 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page